| Name | Title | Contact Details |
|---|
Group Health Plan is a West Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mission Community Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Mission Community Hospital is based in Panorama City, CA. You can find more information on Mission Community Hospital at www.mchonline.org
Coffey Communications, Inc., is the leading provider of custom communication products for the health care industry. For more than 19 years, we have been providing clients with a full line of communication tools including: Publications for hospitals and
digiChart Announces New Executives and New Offices July 15, 2010 BRENTWOOD, Tenn.--(BUSINESS WIRE)--digiChart, Inc. today announced the appointment of two new members to its executive team, Bob Allen and Stephen Faris. The company also announced the relocation of its headquarters to Brentwood, TN, a nearby suburb of Nashville, TN. Bob Allen joins digiChart as National Director of Sales. Mr. Allen will be responsible for all the sales and marketing efforts of the company. Most recently, he served as Vice President of Sales in McKessons Physician Practice Solutions business. He brings over 20 years experience in sales and healthcare technology. Stephen Faris will serve as Vice President of Technology, leading digiCharts product development and technical operations. He previously served as Chief Technology Officer for Healthgate Data Corporation and has extensive experience consulting with companies on their technology and applications strategies. We are excited two exceptional leaders such as Bob and Stephen join our executive team, said digiChart CEO Bill Bates. We are growing and moving forward with exciting initiatives to fully connect OB-GYN care. Bob and Stephens experience will serve us well. They will be central to our success. digiChart also announced the relocation of its headquarters to Brentwood, TN, a nearby suburb of Nashville, TN. The move positions the leader in OB-GYN electronic medical records and practice management systems software for its growth plans and will enable improved service and support for its customers throughout the United States. The Nashville area is a hub for the healthcare, said COO Shelley Predmore. We have enjoyed a rewarding history of growth and success from being in the center of the industrys activities and will continue to do so. Our new offices offer us a state-of-the-art training center for our clients and better consolidate our overall operations. The space will serve us for years to come as we serve our customers. The companys new address is: digiChart, Inc. 100 Winner's Circle, Suite 450 Brentwood, TN 37027 About digiChart, Inc. (www.digichart.com) Based in Brentwood, TN, digiChart, Inc. is a leader in healthcare information technology solutions and services. Dedicated to improving women's healthcare, digiChart provides electronic health record (EHR) and practice management system (PMS) solutions, along with the related training, implementation and workflow improvement services. OB-GYN practices across the country use digiChart's solutions to streamline and optimize their practices clinically and inancially, as well as achieve higher rates of patient satisfaction. Every day, over 100,000 active pregnancies and nearly 1,800,000 womens records are managed through digiCharts solutions. digiChart is a MedCare company. MedCare is a althcare-focused fund invested in a portfolio of healthcare services, healthcare IT and medical device companies with combined revenues of over $350M. Contacts digiChart, Inc. Shelley Predmore, Chief Operating Officer, 615-312-1630 ore@digichart.com
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.